A Phase 1 trial found that a freeze-dried, temperature-stable experimental tuberculosis vaccine was safe, well-tolerated and elicited robust antigen-specific serum antibody and Th1-type cellular immune responses.
The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and - for the first time in over a decade - TB deaths have increased. Research breakthroughs – such as new vaccines – are needed to rapidly reduce the number of new cases...
Vaccine developer Aeras and CMO (contract manufacturing organization) IDT Biologika have formed a strategic partnership that includes the acquisition of Aeras's Biopharmaceutical Development Center (BDC) manufacturing facility by IDT.
With the goal of developing a thermostable tuberculosis vaccine, IDRI (Infectious Disease Research Institute) was awarded a contract from the NIH’s National Institute of Allergy and Infectious Diseases that could be worth up to $11.9m.
Specialty vaccine company PaxVax has acquired the oral typhoid vaccine Vivotif from Crucell, as well as its manufacturing facility in Thörishaus, Switzerland. Financial terms of the transaction were not disclosed.